The trial prospectively shows that the REGN-COV2 antibody cocktail "significantly reduced virus levels and the need for further medical attention," new data involved an additional 524 patients and met its clinical endpoint of reducing medical visits. It's shared the results with the FDA, which is evaluating a possible Emergency Use Authorization. Treatment with REGN-COV2 reduced COVID-19-related medical visits by 57% - and by 72% in patients with one or more risk. factors.
